Gut Microbiome-Based Management of Patients With Heart Failure JACC Review Topic of the Week

Despite therapeutic advances, chronic heart failure (HF) is still associated with significant risk of morbidity and mortality. The course of disease and responses to therapies vary widely among individuals with HF, highlighting the need for precision medicine approaches. Gut microbiome stands to be an important aspect of precision medicine in HF. Exploratory clinical studies have revealed shared patterns of gut microbiome dysregulation in this disease, with mechanistic animal studies providing evidence for active involvement of the gut microbiome in development and pathophysiology of HF. Deeper insights into gut microbiome-host interactions in patients with HF promise to deliver novel disease biomarkers, preventative and therapeutic targets, and improve disease risk stratification. This knowledge may enable a paradigm shift in how we care for patients with HF, and pave the path toward improved clinical outcomes through personalized HF care.(J Am Coll Cardiol 2023;81:1729-1739) & COPY; 2023 by the American College of Cardiology Foundation.

Automated summary

Despite therapeutic advances, chronic heart failure (HF) still poses significant risks. Precision medicine approaches, especially in understanding the role of gut microbiome dysregulation, have the potential to provide novel biomarkers, therapeutic targets, and improved disease risk stratification. Deeper insights into gut microbiome-host interactions may pave the way toward personalized HF care and improved clinical outcomes.